Screener
MapLight Therapeutics, Inc. MPLT Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $53,684 | $19,787 |
| General and administrative | 10,819 | 3,756 |
| Total operating expenses | 64,503 | 23,543 |
| Loss from operations | (64,503) | (23,543) |
| Other income, net: | ||
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s other operating expenses?
- MapLight Therapeutics, Inc. (MPLT) reported other operating expenses of $64.5M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s other operating expenses changed year-over-year?
- MapLight Therapeutics, Inc.'s other operating expenses increased by 174.0% year-over-year, from $23.54M to $64.5M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about MapLight Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude